Overview
This Module is part of the MHRA/DIA Excellence in Pharmacovigilance training course
This module aims also to provide the background for understanding drug-related risks, and to present recent developments regarding risk communication.
In accordance with the GVP Module V on Risk Management System, risk management plans (RMPs) should be submitted by companies to propose activities aiming to identify, characterise or minimise risks associated with medicinal products. Given the potential public health implications and costs of such interventions, RMPs should be based on robust epidemiological methods.
Program Committee
-
Gaby L. Danan, MD, PhD Pharmacovigilance Expert
GLD, France -
Phil Tregunno Deputy Director - Patient Safety Monitoring
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Have an account?